The Role of Microbiome in Colorectal Cancer

Benjamin Weinberg

Pancreatic Cysts - Guidelines Based Management

AdventHealth

V. Shami

How Recent Data Impacts Pancreatic Cancer Management

Integrity CE

M. Pishvaian

Surveillance Imaging in Solid Tumors: More Complicated Than It Appea…

ecancer

C. Booth

ASCO® GI 2025 Insights: Impact of UGT1A1*28 Polymorphism on Treatmen…

Insights from 2025 ASCO® GI Annual Meeting

M. Abdelrahim

ASCO® GI 2025 Insights: Real-World Evidence of Nanoliposomal Irinote…

Insights from 2025 ASCO® GI Annual Meeting

T. Shirakawa

DDW 2024 Highlights: Pancreatic Cancer Screening in High Risk Indivi…

DDW 2024 Conference Coverage

T. Kachaamy

Overcoming Clinical Barriers: Integrating Liposomal Irinotecan Into …

Massachusetts General Hospital Cancer Center

P. Pathak

ASCO® 2024 Insights: "The GIANT Trial (EA2186) - Gem & nab-Paclitaxe…

2024 ASCO® Annual Meeting Insights Hub

E. Dotan

ESMO 2024 Summary: Latest Advances in Targeted Therapies for Pancrea…

2024 ESMO Annual Meeting Insights Hub

D. Melisi

ASCO® GI 2025 Insights: Phase 1b Study of Gemcitabine & Nab-Paclitax…

Insights from 2025 ASCO® GI Annual Meeting

S. Pant

Pancreas Cancer: Update and Review

Scripps Health

W. Coyle

Debates in Neoadjuvant Therapy in Resectable Pancreatic Cancer: Why …

Integrity CE

L. Zheng

NAPOLI-3 Trial: Efficacy & Safety of Liposomal Irinotecan in 1L Meta…

Roberto Pazo-Cid

Updates in Perioperative Therapy of Pancreatic Cancer

Horizon CME

P. Philip

Pancreatic Adenocarcinoma and Neuroendocrine Tumors - An Update

AdventHealth

M. Tejani

ASCO® GI 2025 Insights: Geriatric and QoL Assessments on Gem/Nab-Pac…

Insights from 2025 ASCO® GI Annual Meeting

E. Dotan

Optimizing 1L Treatment for Metastatic Pancreatic Cancer: Evaluating…

Angelo Pirozzi

Targeting KRAS in Pancreatic Cancer

Harshabad Singh

NORPACT-1 Trial Updates: Neoadjuvant FOLFIRINOX vs. Upfront Surgery …

Yale Cancer Center

J. Lacy